# Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan

> **NCT02741310** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 34 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Placebo
- **DRUG:** Sumatriptan
- **DRUG:** Erenumab

## Key facts

- **NCT ID:** NCT02741310
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-22
- **Primary completion:** 2016-08-11
- **Final completion:** 2016-08-11
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02741310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02741310, "Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02741310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*